Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Cell & gene therapy, Cancer

Now for the High-Hanging Fruit

Recent approvals from both regulatory agencies and health technology assessment bodies are showing that cell and gene therapies can be commercially successful. And though it’s right to be delighted that these fantastic technologies are beginning to treat and, in some cases, cure patients with life-threatening diseases, we should also recognize that the field is still in its infancy.

We are only just beginning to see the fruits of years’ of investigation into understanding the role of lymphocytes in controlling cancer – going all the way back to tumor-infiltrating lymphocytes. The question for the field has been how we can harness and direct the immune system to fight cancer. The field has shown that it is possible to put a chimeric antigen receptor (CAR) on a T-cell, have it recognize an antigen on the cancer cell and activate the intercellular machinery. CD19 is the target for both of the products on the market today and is really the core of the cell therapy field. The fact that it is only expressed in B-cells allows us to specially target cancers arising from this type of cell – such as B-cell lymphomas, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Miguel Forte

Miguel Forte is Chief Executive Officer of Zelluna Immunotherapy and Chief Commercialization Officer and Chair of the Commercialization Committee, International Society of Cellular Therapy.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register